Science Will WinTM

We believe science can cure every human disease. And we're going all in. 

Find out how

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500.png
young_woman_getting_vaccinated_1000x450.png

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Learn More

COVID-19 SCIENTIFIC RESOURCES

Our Science
COVID-19 SCIENTIFIC RESOURCES
COVID-19 SCIENTIFIC RESOURCES

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

More Here

Global Survey Results: Cancer & Aging

News
World_Cancer_Day_790X500.jpg
World_Cancer_Day_1000X450.jpg

Global Survey Results: Cancer & Aging

This World Cancer Day, we surveyed older people living with cancer and their caregivers.

Learn about the findings

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

THE ANTIGEN: #COVID19 PODCAST

Podcasts
the_antigen_image_380x700.png
the_antigen_image_1000x450.jpg

THE ANTIGEN: #COVID19 PODCAST

Season 2 of The Antigen podcast focuses on COVID-19, Pfizer’s response to the crisis and more.

Listen & subscribe here

VISIT OUR COVID-19 HUB

Our Science
GettyImages-1208505315_790x500.png
GettyImages-1208505315_1000x450_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

Latest News

European Medicines Agency Accepts Pfizer’s…

If approved, the vaccine would help protect adults against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults…
Read more